Physician preferences for non-metastatic castration-resistant prostate cancer treatment.

ABSTRACT:

Background

Recent approvals of second-generation androgen receptor inhibitors (SGARIs) have changed the treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC). These SGARIs have similar efficacy but differ in safety profiles. We used a discrete choice experiment to explore how United States physicians make treatment decisions between adverse events (AEs) and survival gains in nmCRPC, a largely asymptomatic disease.

Methods

Treating physicians (n = 149) participated in an online survey that included 14 treatment choice questions, each comparing 2 hypothetical treatment profiles, which varied in terms of 5 safety and 2 efficacy attributes. We described safety attributes (fatigue, skin rash, cognitive problems, falls, and fractures) in terms of sev

SUBMITTER: Srinivas S 

PROVIDER: S-EPMC7310549 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature